Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders

Thrombosis Research

Volumn 110, Issue 4, 2003, Pages 243-247

  Özcan, Mehmet Ali ^a   Çömlekçi, Abdurrahman ^a   Demirkan, Fatih ^a   Yüksel, Faize ^a   Sari, Ismail ^a   Demir, Tevfik ^a   Özsan, Güner Hayri ^a   Örük, Gonca ^a   Yeşil, Sena ^a   Ündar, Bülent ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Hyperthyroidism; Hypothyroidism; Subclinical hypothyroidism; Thyroid; Tissue factor pathway inhibitor

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; THYROID HORMONE; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EUTHYROIDISM; FEMALE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MALE; PRIORITY JOURNAL; THYROID DISEASE; THYROID FUNCTION;

EID: 10744231132     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00408-0     Document Type: Article

References (29)

1. Hofbauer L.C., Heufelder A.E. Coagulation disorders in thyroid diseases. Eur. J. Endocrinol. 136:1997;1-7.
2. Myrup B., Bregengard C., Faber J. Primary haemostasis in thyroid disease. J. Intern. Med. 238:1995;59-63.
3. Parker J.L., Lawson D.H. Death from thyrotoxicosis. Lancet. 2(7834):1973;849-895.
4. Rogers J.S., Shane S.R., Jencks F.S. Factor VIII activity and thyroid function. Ann. Intern. Med. 97:1982;713-716.
5. Marongiu F., Conti M., Mameli G., Murtas M.L., Balzano S., Sorano G.et al. Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment. J. Endocrinol. Invest. 11:1988;723-725.
6. Morikawa Y., Morikawa A., Makino I. Relationship of thyroid states and serum thrombomodulin (TM) levels in patients with Graves disease: TM, a possible new marker of the peripheral activity of thyroid hormones. J. Clin. Endocrinol. Metab. 76:1993;609-614.
7. Ford H.C., Carter J.M. Haemostasis in hypothyroidism. Postgrad. Med. J. 66:1990;280-284.
8. Rennie J.A., Bewsher P.D., Murchison L.E., Ogston E. Coagulation and fibrinolysis in thyroid disease. Acta Haematol. 59:1978;171-177.
9. Lindahl A.K. Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle. Cardiovasc. Res. 33:1997;286-291.
10. Sandset P.M., Roise O., Aasen O.A., Abilgaard U. Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases. Haemostasis. 19:1989;189-195.
11. Creasey A.A., Chang A.C., Feigen L., Wun T.C., Taylor F.B. Jr., Hinshaw L.B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J. Clin. Invest. 91:1993;2850-2856.
12. Shimura M., Wada H., Nakasaki T., Hiyoyama K., Mori Y., Nishikawa M.et al. Increased truncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am. J. Hematol. 60:1999;94-98.
13. Iversen N., Lindahl A.K., Abildgaard U. Elevated tissue factor pathway inhibitor in malignant disease: relation to cancer type and hypercoagulation. Br. J. Haematol. 102:1998;889-895.
14. Sandset P.M., Sirnes P.A., Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br. J. Haematol. 72:1989;391-396.
15. Idell S. Extravascular coagulation and fibrin deposition in acute lung injury. New Horiz. 2:1994;566-574.
16. Leurs P.B., vanOerle R., Hamulyak K., Wolffenbuttel B.H. Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes. 44:1995;80-84.
17. Kario K., Matsuo T., Yamada T., Matsuo M. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb. Haemost. 71:1994;275-279.
18. Akarsu M., Demirkan F., Özsan G.H., Önen F., Yüksel F., Özkan S.et al. Increased levels of tissue factor pathway inhibitor may reflect disease activity and play a role in thrombotic tendency in Behçet's disease. Am. J. Hematol. 68:2001;225-230.
19. Morishita E., Hashimoto T., Asakura H., Saito M., Yamazaki M., Aoshima K.et al. Increased plasma levels of free tissue factor pathway inhibitor in patients with Graves' disease. Thromb. Haemost. 79:1998;919-923.
20. Evered D.C., Ormston B.J., Smith P.A., Hall R., Bird T. Grades of hypothyroidism. Br. Med. J. 1(5854):1973;657-662.
21. 111Indium labeled platelet kinetics and platelet associated immunoglobulins G and M. J. Clin. Endocrinol. Metab. 70:1990;491-496.
22. Rapaport S.I. The extrinsic pathway inhibitor. A regulator of tissue factor dependent blood coagulation. Thromb. Haemost. 66:1991;6-15.
23. Broze G.J. Tissue factor pathway inhibitor. Thromb. Haemost. 74:1995;90-93.
24. Staels B., van Tol A., Chan L., Will H., Verhoeven G., Auwerx J. Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase and low density lipoprotein receptor in rats. Endocrinology. 127:1990;1144-1152.
25. Davidson N.O., Powell L.M., Wallis S.C., Scott J. Thyroid hormone modulates the introduction of a stop codon in rat liver apoprotein B messenger RNA. J. Biol. Chem. 263:1988;13482-13485.
26. Davidson N.O., Carlos R.C., Lukaszwicz A.M. Apolipoprotein B mRNA editing is modulated by thyroid hormone analogs but not growth hormone administration in the rat. Mol. Endocrinol. 4:1990;779-785.
27. Li Y., Chen H., Tan J., Wang X., Liang H., Sun X. Impaired release of tissue plasminogen activator from the endothelium in Graves' disease-indicator of endothelial dysfunction and reduced fibrinolytic capacity. Eur. J. Clin. Invest. 28:1998;1050-1054.
28. Burggraaf J., Lalezari S., Emeis J.J., Vischer U.M., deMeyer P.H., Pijl H.et al. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid. 2:2001;153-160.
29. Resnick N., Gimbrone M.A. Hemodynamic forces are complex regulators of endothelial gene expression. FASEB J. 9:1995;874-882.